Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-κB activity in human macrophages in vitro

Rubin, 2004, Immunomodulatory activity and effectiveness of macrolides in chronic airway disease, Chest, 125, 70S, 10.1378/chest.125.2_suppl.70S Giamarellos-Bourboulis, 2008, Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators, Int J Antimicrob Agents, 31, 12, 10.1016/j.ijantimicag.2007.08.001 Gotfried, 2004, Macrolides for the treatment of chronic sinusitis, asthma, and COPD, Chest, 125, 52S, 10.1378/chest.125.2_suppl.52S Banerjee, 2004, The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial, Treat Respir Med, 3, 59, 10.2165/00151829-200403010-00007 Culic, 2001, Anti-inflammatory effects of macrolide antibiotics, Eur J Pharmacol, 429, 209, 10.1016/S0014-2999(01)01321-8 Lopez-Boado, 2008, Macrolides as immunomodulatory medications for the therapy of chronic lung diseases, Curr Opin Pharmacol, 8, 286, 10.1016/j.coph.2008.01.010 Barnes, 2000, Chronic obstructive pulmonary disease, N Engl J Med, 343, 269, 10.1056/NEJM200007273430407 Rytila, 2006, Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD, Respir Res, 7, 69, 10.1186/1465-9921-7-69 Saetta, 2001, Cellular and structural bases of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 163, 1304, 10.1164/ajrccm.163.6.2009116 Hogg, 2004, The nature of small-airway obstruction in chronic obstructive pulmonary disease, N Engl J Med, 350, 2645, 10.1056/NEJMoa032158 Kirkham, 2006, Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy, Pharmacol Ther, 111, 476, 10.1016/j.pharmthera.2005.10.015 Barnes, 2004, Alveolar macrophages in chronic obstructive pulmonary disease (COPD), Cell Mol Biol (Noisy-le-grand), 50 Barnes, 2003, Chronic obstructive pulmonary disease: molecular and cellular mechanisms, Eur Respir J, 22, 672, 10.1183/09031936.03.00040703 Keatings, 1996, Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma, Am J Respir Crit Care Med, 153, 530, 10.1164/ajrccm.153.2.8564092 Cosio, 2004, Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages, J Exp Med, 200, 689, 10.1084/jem.20040416 Urnov, 2001, Chromatin remodeling and transcriptional activation: the cast (in order of appearance), Oncogene, 20, 2991, 10.1038/sj.onc.1204323 Tomita, 2003, The effect of oxidative stress on histone acetylation and IL-8 release, Biochem Biophys Res Commun, 301, 572, 10.1016/S0006-291X(02)03029-2 Ito, 2005, Decreased histone deacetylase activity in chronic obstructive pulmonary disease, N Engl J Med, 352, 1967, 10.1056/NEJMoa041892 Barnes, 2006, Reduced histone deacetylase in COPD: clinical implications, Chest, 129, 151, 10.1378/chest.129.1.151 de Ruijter, 2003, Histone deacetylases (HDACs): characterization of the classical HDAC family, Biochem J, 370, 737, 10.1042/bj20021321 Ito, 2000, Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12, Mol Cell Biol, 20, 6891, 10.1128/MCB.20.18.6891-6903.2000 Barnes, 2004, Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase, Lancet, 363, 731, 10.1016/S0140-6736(04)15650-X Barnes, 2003, New concepts in chronic obstructive pulmonary disease, Annu Rev Med, 54, 113, 10.1146/annurev.med.54.101601.152209 Culpitt, 2003, Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 167, 24, 10.1164/rccm.200204-298OC Adcock, 2005, Histone deacetylation: an important mechanism in inflammatory lung diseases, COPD, 2, 445, 10.1080/15412550500346683 Barnes, 2005, Histone acetylation and deacetylation: importance in inflammatory lung diseases, Eur Respir J, 25, 552, 10.1183/09031936.05.00117504 Yang, 2006, Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages, Am J Physiol Lung Cell Mol Physiol, 291, L46, 10.1152/ajplung.00241.2005 Sundstrom, 1976, Establishment and characterization of a human histiocytic lymphoma cell line (U-937), Int J Cancer, 17, 565, 10.1002/ijc.2910170504 Verhoeckx, 2004, A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line, Proteomics, 4, 1014, 10.1002/pmic.200300669 Izeboud, 2000, Stereoselectivity at the beta2-adrenoceptor on macrophages is a major determinant of the anti-inflammatory effects of beta2-agonists, Naunyn Schmiedebergs Arch Pharmacol, 362, 184, 10.1007/s002100000281 Chen, 2005, HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin, Cancer Chemother Pharmacol, 56, 212, 10.1007/s00280-004-0960-5 Carp, 1978, Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants, Am Rev Respir Dis, 118, 617 Martey, 2004, Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer, Am J Physiol Lung Cell Mol Physiol, 287, L981, 10.1152/ajplung.00239.2003 Moodie, 2004, Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells, FASEB J, 18, 1897, 10.1096/fj.04-1506fje Kramer, 2003, The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2, EMBO J, 22, 3411, 10.1093/emboj/cdg315 de Torres, 2006, Gender and chronic obstructive pulmonary disease in high-risk smokers, Respiration, 73, 306, 10.1159/000090051 Crosbie, 2009, Long-term macrolide therapy in chronic inflammatory airway diseases, Eur Respir J, 33, 171, 10.1183/09031936.00042208 Suzuki, 2001, Erythromycin and common cold in COPD, Chest, 120, 730, 10.1378/chest.120.3.730 Seemungal, 2008, Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations, Am J Respir Crit Care Med, 178, 1139, 10.1164/rccm.200801-145OC He, 2010, Effect of 6months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease, Respiration, 80, 445, 10.1159/000321374 Hoshino, 2001, Cytotoxic effects of cigarette smoke extract on an alveolar type II cell-derived cell line, Am J Physiol Lung Cell Mol Physiol, 281, L509, 10.1152/ajplung.2001.281.2.L509 Rahman, 2006, Oxidative stress and redox regulation of lung inflammation in COPD, Eur Respir J, 28, 219, 10.1183/09031936.06.00053805 Rahman, 2003, Ergothioneine inhibits oxidative stress- and TNF-alpha-induced NF-kappa B activation and interleukin-8 release in alveolar epithelial cells, Biochem Biophys Res Commun, 302, 860, 10.1016/S0006-291X(03)00224-9 Desaki, 2004, Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation, Antimicrob Agents Chemother, 48, 1581, 10.1128/AAC.48.5.1581-1585.2004 Wu, 2009, In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells, Int Immunopharmacol, 9, 1105, 10.1016/j.intimp.2009.05.008 Wu, 2007, Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro, Immunopharmacol Immunotoxicol, 29, 587, 10.1080/08923970701692841 Adcock, 2005, Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response, Antioxid Redox Signal, 7, 144, 10.1089/ars.2005.7.144 Rahman, 2002, Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation, Mol Cell Biochem, 234–235, 239, 10.1023/A:1015905010086 Rajendrasozhan, 2009, Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD, COPD, 6, 291, 10.1080/15412550903049132 Ito, 2004, Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration, Biochem Biophys Res Commun, 315, 240, 10.1016/j.bbrc.2004.01.046 Ito, 2006, Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression, J Exp Med, 203, 7, 10.1084/jem.20050466 Ashburner, 2001, The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression, Mol Cell Biol, 21, 7065, 10.1128/MCB.21.20.7065-7077.2001 Chen, 2001, Duration of nuclear NF-kappaB action regulated by reversible acetylation, Science, 293, 1653, 10.1126/science.1062374 Zhong, 2002, The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1, Mol Cell, 9, 625, 10.1016/S1097-2765(02)00477-X